Released Sep 14, 2017, after the close
10-Q filed Sep 14, 2017, 45 days after period end · 0001654954-17-008465
Q3 2017 · 10-Q
Revenue$3.98M$3.98M no prior Q3 2016 on file+1.5% vs Q2 2017
Net Income-$162.98K-$162.98K N/M vs Q3 2016N/M vs Q2 2017
EPS Diluted-$0.01-$0.01 N/M vs Q3 2016N/M vs Q2 2017
Gross Profit$928,110−34.9%
Operating Income-$194,254N/M
Operating Cash Flow-$478,396N/M
Free Cash Flowderived-$518,951N/M
Margins · derived
Gross margin23.3%
Operating margin-4.9%
Net margin-4.1%
What the release said
The release
Same quarter
| Metric | Q3 2017 | Q3 2016 | Q3 2015 | Q3 2014 |
|---|---|---|---|---|
| Revenue | $3.98M | — | — | — |
| Net Income | -$162.98K | -$130.47K | $453.97K | $597.06K |
| EPS Diluted | -$0.01 | -$0.01 | $0.02 | $0.03 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pharma-Bio Serv, Inc. · CIK 1304161 · Engraved from SEC EDGAR